(R)-N-(1-(5-(Trifluoromethyl)pyridin-2-yl)ethyl)cyclopropanamine, 100mg

Infinity corrected plan phase S40x/0.65 objective. Working distance 0.36 mm

Methyl 8-bromooctanoate, 97%, 10g

Methyl 3-amino-5-bromo-2-methylbenzoate, 95.0%, 5g

FMOC-3,5-DIIODO-L-TYROSINE, 95%, 10g

1,3,5-Tris[(3,3,3-trifluoropropyl)methyl]-cyclotrisiloxane, 99.00%, 100g

1,2-Dibromo-4,5-methylenedioxybenzene, 95.0%, 5g

Sodium formaldehyde sulfoxylate dihydrate, >98%, for synthesis, 500 g, plastic packaging.

Bis(4-bromophenyl) Ether>97.0%(GC)25g

1-(4-Amino-phenyl)-3-methyl-1,2,4-triazole, 95.0%, 250mg

4-methyl-2-oxo-1,3-dioxane, 95%, 1g

Quetiapine Hemifumarate>98.0%(HPLC)(T)25g

1-(4-Chlorobenzyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea, 98%, 1g